Phase II studies with L19-IL2 in patients with metastatic melanoma had shown that some patients enjoyed major durable responses with favorable safety profile [53, 54] but more than 50% of the subjects did not achieve a partial response. This evidence concerns the gene IL2 and metastatic melanoma.